Arcturus Secures Strategic Collaboration with Thermo Fisher for Cystic Fibrosis Drug ARCT-032
ARCT sits 22% above its 52-week low of $5.85.
Summary
Arcturus Therapeutics has partnered with Thermo Fisher Scientific for up to $80 million in manufacturing and clinical services to advance its lead cystic fibrosis drug, ARCT-032, through Phase 3 and potential commercialization.
Key Events · M&A and Partnerships · ARCT
-
Strategic Collaboration for ARCT-032
Arcturus entered into a Master Services Agreement and Project Agreement with Thermo Fisher Scientific for contract development, manufacturing (CDMO), and clinical research organization (CRO) services for its investigational mRNA therapeutic for cystic fibrosis, ARCT-032.
-
Significant Service Commitment
Thermo Fisher will provide up to $40 million in clinical manufacturing services for ARCT-032, and Arcturus will engage PPD (Thermo Fisher's CRO affiliate) for up to $40 million in CRO services.
-
Exclusive Commercial Rights
Upon regulatory approval of ARCT-032, Thermo Fisher would receive exclusive commercial manufacturing rights for the product for a specified duration.
-
Advancement of Key Pipeline Asset
This partnership provides crucial support for the Phase 3 development and potential commercialization of ARCT-032, a key asset for Arcturus, especially in light of the company's recent financial performance.
Analysis · ARCT · Life Sciences
This collaboration with Thermo Fisher Scientific provides critical contract development, manufacturing, and clinical research services for Arcturus' investigational cystic fibrosis drug, ARCT-032. The agreement, valued at up to $80 million in services, significantly de-risks the advancement of ARCT-032 into Phase 3 and towards potential commercialization. This is particularly important given Arcturus' recent financial challenges, as it secures essential operational support and expertise from a leading industry partner.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARCT was trading at $7.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $195.8M. The 52-week trading range was $5.85 to $24.17. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.